Laflunimus is an immunosuppressant and an analog of the active metabolite A771726 of leflunomide; it functions as an orally active dihydroorotate dehydrogenase (DHODH) inhibitor; it inhibits immunoglobulin (Ig) secretion, with IC50 values of 2.5 μM and 2 μM for IgM and IgG, respectively; it also acts as an inhibitor of prostaglandin endoperoxide synthase (PGHS)-1 and -2; it suppresses the secondary anti-sheep red blood cell (SRBC) antibody response in vivo, with an ID50 of 38 mg/kg; it dose-dependently inhibits circulating anti-SRBC IgG levels in mice when administered orally.